• Contact Us
Wednesday, July 2, 2025
Health Business
Advertisement
  • Home
  • News
    Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships

    Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships

    Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

    Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

    Kenya Launches National Employer Compliance Initiative to Power Universal Health Coverage

    Kenya Launches National Employer Compliance Initiative to Power Universal Health Coverage

    Why Road Safety for Pedestrians in Nairobi Remains an Afterthought

    Why Road Safety for Pedestrians in Nairobi Remains an Afterthought

  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos
  • Home
  • News
    Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships

    Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships

    Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

    Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

    Kenya Launches National Employer Compliance Initiative to Power Universal Health Coverage

    Kenya Launches National Employer Compliance Initiative to Power Universal Health Coverage

    Why Road Safety for Pedestrians in Nairobi Remains an Afterthought

    Why Road Safety for Pedestrians in Nairobi Remains an Afterthought

  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos
No Result
View All Result
Health Business
No Result
View All Result

‘Revolutionary’ drug for prostate cancer

by Health Business
October 1, 2019
in Medical Research, News
0
‘Revolutionary’ drug for prostate cancer
Share This:

Olaparib could become a revolutionary treatment for prostate cancer – the first genetically targeted drug for fighting the disease, say experts.

The precision medicine is already used by the NHS for ovarian cancer and has been called a game-changer by cancer doctors.

A cancer conference heard how, in trials, it slowed tumour growth in men with advanced prostate cancer.

This could improve survival for some men, researchers hope.

Experts say it could be made available to patients in the next couple of years.

The drug, made by AstraZeneca, was fast-tracked to NHS ovarian cancer patients in England, paid for through the Cancer Drugs Fund, in July.

Precision medicine

Olaparib, also called Lynparza, works by targeting and killing cancer cells with faulty genetic code, while sparing normal cells with healthy DNA.

It won’t work for everyone with prostate cancer, but it is effective for some men with the disease, say researchers.

Patients can be tested to see if they have the genetic errors that the drug can attack – faulty DNA repair genes including BRCA1 and BRCA2.

This precision approach means the patients most likely to benefit will be treated, sparing them potential side-effects from other drugs that may not work as well for them.

In the trial, doctors compared olaparib with two other commonly prescribed prostate drugs (hormone treatments called abiraterone and enzalutamide).

It appeared to delay cancer growth by months, which researchers say should hopefully mean men can survive for longer even when their disease is advanced. They will be monitoring patients to confirm this.

About prostate cancer

One in eight men will be diagnosed with prostate cancer in their lifetime. It mainly affects men over the age of 50 and the risk increases with age.

Not all of these tumours need immediate treatment. If the cancer is at an early stage and not causing symptoms, doctors may instead suggest careful monitoring.

Some cases are more aggressive and need treatment but can be cured if caught early enough.

Other cases may only be diagnosed at a late stage when the cancer has spread and cannot be cured.

All treatments, including olaparib, can have side-effects.

Doctors can talk advise patients about what might be the best treatment for them.

Prof Johann de Bono, from the Institute of Cancer Research, London, who co-led the drug trial, said: “It’s essential that we become smarter in the way we treat prostate cancer, so that every man gets the treatment that will be of greatest benefit for them.”

Dr Matthew Hobbs, from the charity Prostate Cancer UK, said: “This hugely exciting result represents a revolution in the treatment of prostate cancer. It finally brings prostate cancer medicine into the 21st Century by giving us, for the first time ever, a therapy that makes use of genetic testing of the tumour to work out which men will benefit.

“This kind of precision medicine approach is already used to treat other cancers, and we hope olaparib will become the first of many treatments for prostate cancer which are based on this sort of detailed understanding of an individual man’s tumour.”

Prof Nicholas James from Cancer Research UK said: “Tailoring cancer treatment according to a tumour’s specific genetic faults is a core part of care in breast, lung or skin cancers to name a few, and has helped us give patients the treatments that are most likely to work for them. But with prostate cancer, we’ve been treating everyone the same way.

“Matching patients to the most appropriate treatment for their tumour type could radically change the way we treat prostate cancer. In this case, olaparib only slowed the disease down for a few months in a subset of men, but the approach itself is full of possibilities. And if we get to a point where we can tailor treatments in prostate cancer from an early stage, we can give every patient the best chance of being successfully treated.”

Share This:
Previous Post

Sale of heartburn drug Zantac suspended over cancer fears

Next Post

Early diagnosis can help cure most childhood cancers

Related Posts

Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships
News

Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships

July 1, 2025
Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines
News

Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

June 25, 2025
Kenya Launches National Employer Compliance Initiative to Power Universal Health Coverage
News

Kenya Launches National Employer Compliance Initiative to Power Universal Health Coverage

June 25, 2025
Next Post
Cancer scientists have ignored African DNA in the search for cures

Early diagnosis can help cure most childhood cancers

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

No Result
View All Result

Follow Us

Most Read

  • Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

    Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

    0 shares
    Share 0 Tweet 0
  • Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships

    0 shares
    Share 0 Tweet 0
  • Why Road Safety for Pedestrians in Nairobi Remains an Afterthought

    0 shares
    Share 0 Tweet 0
Health Business

Health Business contains need-to-know features, news and case studies that explain the administrative and commercial issues affecting healthcare and hospital management. Health Business supports several high profile exhibitions - coverage of which is always timed for maximum impact. Regular topics include ICT, Finance/Funding, Facilities Management, Security, Health & Safety. Contributors range from government ministers through to top-level health administrators and association chairs.

Top Stories

Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships

Kenya to Expand its Family Planning Access through availability of Self-Injection choices and Public-Private Partnerships

July 1, 2025
Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

Kenya Joins Pfizer’s Global ‘Accord for a Healthier World’: A Boost for Equitable Access to Life-Saving Medicines and Vaccines

June 25, 2025
Kenya Launches National Employer Compliance Initiative to Power Universal Health Coverage

Kenya Launches National Employer Compliance Initiative to Power Universal Health Coverage

June 25, 2025

Interests

  • Events
  • Finance
  • Government
  • Magazines
  • Medical Research
  • News
  • Politics & Policy
  • Providers
  • Public Health
  • Regulation, Enforcement & Compliance
  • Technology
  • Videos

Follow Us

  • Contact Us

© 2019 | Site by Mark & Ryse.

No Result
View All Result
  • Home
  • News
  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos

© 2019 | Site by Mark & Ryse.